Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rekah Pharmaceutical ProdXTAE:REKA 57 EV-to-FCF is 77.44 as of Jul. 18, 2026, which is 341% above its 10-year median of 17.58. GuruFocus rates XTAE:REKA with a GF Score™ of 57/100 and a GF Value™ of ₪13.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 564 Drug Manufacturers companies, Rekah Pharmaceutical Prod ranks worse than 82.09% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rekah Pharmaceutical Prod's Enterprise Value is ₪249.3 Mil.
Rekah Pharmaceutical Prod's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₪3.2 Mil. Therefore, Rekah Pharmaceutical Prod's EV-to-FCF for today is 77.44.
The historical rank and industry rank for Rekah Pharmaceutical Prod's EV-to-FCF or its related term are showing as below:
XTAE:REKA'
s EV-to-FCF Range Over the Past 10 Years
Min: -99.73 Med: 17.58 Max: 224.8
Current: 75.34
During the past 13 years, the highest EV-to-FCF of Rekah Pharmaceutical Prod was 224.80. The lowest was -99.73. And the median was 17.58.
XTAE:REKA's EV-to-FCF is ranked worse than 82.09% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.815
vs XTAE:REKA: 75.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rekah Pharmaceutical Prod's PE Ratio (TTM) for today is calculated as:
Rekah Pharmaceutical Prod's share price for today is ₪10.89.
Rekah Pharmaceutical Prod's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-1.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Rekah Pharmaceutical Prod EV-to-FCF Related Terms
Rekah Pharmaceutical Prod EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:REKA vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's EV-to-FCF falls into.
Rekah Pharmaceutical Prod's current Enterprise Value is ₪249.3 Mil.
Rekah Pharmaceutical Prod's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪3.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod (XTAE:REKA) has a EV-to-FCF of 77.44 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rekah Pharmaceutical Prod and its competitors. This is 341% above median its historical median of 17.58. According to the industry distribution chart, Rekah Pharmaceutical Prod ranks #463 out of 564 companies in the Drug Manufacturers industry, placing it in the top 82.1%.
Is Rekah Pharmaceutical Prod's EV-to-FCF too high?
Rekah Pharmaceutical Prod's current EV-to-FCF of 77.44 is 341% above median its 10-year median of 17.58. The Drug Manufacturers industry median EV-to-FCF is 20.82. Rekah Pharmaceutical Prod's value of 77.44 is 272% above this industry median. Based on the distribution chart, Rekah Pharmaceutical Prod ranks #463 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rekah Pharmaceutical Prod ranks #463 out of 564 companies for EV-to-FCF. This places Rekah Pharmaceutical Prod in the lower half of its industry. The industry median EV-to-FCF is 20.82. Rekah Pharmaceutical Prod's value of 77.44 is 272% above this benchmark. While the company's 10-year median is 17.58 vs. the industry median of 20.82, Rekah Pharmaceutical Prod has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.82, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rekah Pharmaceutical Prod's current EV-to-FCF of 77.44 is 272% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rekah Pharmaceutical Prod and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rekah Pharmaceutical Prod's current EV-to-FCF is 77.44, which is 341% above median its own 10-year median of 17.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.89 — trading 16.6% below its estimated fair value. The current EV-to-FCF is 77.44, which is 341% above median its 10-year median of 17.58 and 272% above the Drug Manufacturers industry median of 20.82. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current EV-to-FCF is 77.44 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪10.89 is trading 16.6% below its estimated GF Value™ of ₪13.05.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
EV-to-FCF: 77.44 (341% above median its 10-year median of 17.58)
GF Value™: ₪13.05 vs. price of ₪10.89 (16.6% below fair value)
Industry Position: 272% above the Drug Manufacturers median (#463 of 564)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
